When Combined with Chemotherapy, Bevacizumab Is Associated with Increased Risk of Death - National Cancer Institute (discusses various tumor types....

Note: this NCI article does not include ovarian cancer but does include platinum/taxane combination therapies (Carboplatin, Taxol); the JAMA paper most likely included ovarian cancer, however, the full text of the article is pay-per-view ($$$)

"The results were published February 2, 2011, in JAMA.":


JAMA abstract:
Treatment-Related Mortality With Bevacizumab in Cancer Patients
A Meta-analysis

"The overall incidence of FAEs (fatal adverse events) with bevacizumab was 2.5%."